Benign Skin Lesion Removal

Number: 0633

Policy

Aetna considers removal of acquired or small (less than 1.5 cm) congenital nevi (moles), cutaneous and subcutaneous neurofibromas, dermatofibromas, dermatosis papulosa nigra, acrochordon (skin tags), pilomatrixomata (slow-growing hard mass underneath the skin that arises from hair follicle matrix cells), sebaceous cysts (pilar and epidermoid cysts), seborrheic keratoses (also known as basal cell papillomas, senile warts or brown warts), or other benign skin lesions, or needle hyfrecation for sebaceous hyperplasia, medically necessary if any of the following criteria is met:

• Biopsy suggests or is indicative of pre-malignancy (e.g., dysplasia) or malignancy; or
• Due to its anatomic location, the lesion has been subject to recurrent trauma/irritation (eg, bra line, waist band, etc.); or
• Lesion appears to be pre-malignant (e.g., actinic keratoses (see CPB 0567 - Actinic Keratoses Treatment), Bowen's disease, dysplastic lesions, dysplastic nevus syndrome, large congenital melanocytic nevi, lentigo maligna, or leukoplakia) or malignantFootnote1* (due to coloration, change in appearance or size, etc. (see note below) especially in a person with personal or family history of melanoma); or
• Skin lesions are causing symptoms (e.g., bleeding, burning, intense itching, or irritation); or
• The lesion has evidence of inflammation (e.g., edema, erythema, or purulence); or
• The lesion is infectious (e.g., warts (verruca vulgaris)); or
• The lesion restricts vision or obstructs a body orifice.

In the absence of any of the above indications, removal of dermatofibromas, dermatosis papulosa nigra, pilomatrixoma, poikiloderma of Civatte (sun aging), sebaceous cysts, seborrheic keratoses, small nevi (moles), or other benign skin lesions, or needle hyfrecation for sebaceous hyperplasia, is considered cosmetic.

Background

A skin lesion is a nonspecific term that refers to any change in the skin surface; it may be benign, malignant or premalignant. Skin lesions may have color (pigment), be raised, flat, large, small, fluid filled or exhibit other characteristics. Common examples of benign skin lesions may include moles (nevi), sebaceous cysts, seborrheic keratoses, skin tags (acrochordon), callouses, corns or warts.

The treatment of benign skin lesions consists of destruction or removal by any of a wide variety of techniques. The removal of a skin lesion can range from a simple biopsy, scraping or shaving of the lesion, to a radical excision that may heal on its own, be closed with sutures (stitches) or require reconstructive techniques involving skin grafts or flaps. Laser, cautery or liquid nitrogen may also be used to remove benign skin lesions. When it is uncertain as to whether or not a lesion is cancerous, excision and laboratory (microscopic) examination is usually necessary.

Seborrheic keratoses are non-cancerous growths of the outer layer of skin.  They are usually brown, but can vary in color from beige to black, and vary in size from a fraction of an inch to more than an inch in diameter. They may occur singly or in clusters on the surface of the skin. They typically has a wart-like texture with a waxy appearance, and have the appearance of being glued or stuck on to skin.  Seborrheic keratoses are most often found on the chest or back, although, they can also be found almost anywhere on the body.  These become more common with age, and most elderly patients develop one or more of these lesions.  Seborrheic keratoses can get irritated by clothing rubbing against them, and their removal may be medically necessary if they itch, get irritated, or bleed easily.  Although seborrheic keratoses are non-cancerous, they may be difficult to distinguish from skin cancer if they turn black.  Seborrheic keratoses may be removed by cryosurgery, curettage, or electrosurgery.

Acquired nevi (moles) can appear anywhere on the skin.  They are usually brown in color, but can be skin colored or pink, light tan to brown, or blue-black.  Moles may be flat or raised and can be various sizes and shapes.  Most appear during the first 20 years of a person's life, although some may not appear until later in life.  Sun exposure increases the number of moles.  The majority of moles are benign.  However, moles that raise suspicion of malignancy are those that change in size, shape or color, and those that bleed, itch, or become painful.  Atypical moles (dysplastic nevi) have an increased risk of developing into melanoma.  Atypical moles are larger than average (greater than 6 mm) and irregular in shape.  They tend to have uneven color with dark brown centers and lighter, sometimes reddish, uneven borders or black dots at edge.  The most common methods of removal include shaving and excision.

Congenital melanocytic nevi occur in approximately 1 % of newborns and are usually classified according to their size.  Giant congenital melanocytic nevi are most simply defined as melanocytic nevi that are greater than 20 cm in largest dimension; whereas small congenital nevi are defined as melanocytic nevi less than 1.5 cm in largest dimension.  Giant congenital melanocytic nevi are associated with an increased risk of the development of melanoma, and are therefore surgically removed.  However, small congenital nevi do not need to be removed as the risk of malignant transformation is thought to be small or none.  The management of intermediate sized congenital nevi is controversial, as the risk of malignant transformation and the lifetime melanoma risk in patients with intermediate sized congenital nevi is not known.

A sebaceous (keratinous) cyst is a slow-growing, benign cyst that contains follicular, keratinous, and sebaceous material.  The sebaceous cyst is firm, globular, movable, and non-tender. These cysts seldom cause discomfort unless the cyst ruptures or becomes infected.  Ranging in size, sebaceous cysts are usually found on the scalp, face, ears, and genitals.  They are formed when the release of sebum from the sebaceous glands in the skin is blocked.  Unless they become infected and painful or large, sebaceous cysts do not require medical attention or treatment, and usually go away on their own.  Infected cysts can be incised and drained, or the entire cyst may be surgically removed.

A skin tag (arochordon) is a benign, soft, moveable, skin-colored growth that hangs from the surface of the skin on a thin piece of tissue called a stalk.  The prevalence of skin tags increases with age.  They appear most often in skin folds of the neck, armpits, trunk, beneath the breasts or in the genital region.  They are painless, but may become painful if thrombosed or if irritated.  They may become irritated if they occur in an area where clothing or jewelry rubs against them.  Skin tags may be removed by excision, cryosurgery, or electrosurgery.

Actinic keratoses are the most common type of premalignant skin lesions, occurring in sun-exposed areas that may give rise to squamous cell carcinomas. They are thought to be caused by years of exposure to the sun.  The lesions are scaly sandpaper-like patches, varying in color from skin-colored to reddish-brown or yellowish-black.  Lesions may be single or multiple.  They are usually painless but may be slightly tender.  Actinic keratoses are discussed in CPB 0567 - Actinic Keratoses Treatment.

Bowen's disease (squamous cell carcinoma in situ) is a pre-malignant lesion, often due to arsenic exposure, that may give rise to squamous cell carcinoma.  Lesions predominantly affect the elderly, and consist of persistent, erythematous, scaly plaques with well-defined margins.  Treatment options include excision, cryotherapy, curettage and cautery, and topical 5-fluorouracil.

Lentigo maligna (Hutchinson's Freckle) is a pre-malignant lesion that may give rise to lentigo maligna melanoma.  These lesions are pigmented macules, often greater than 1 cm in diameter with an irregular border, occurring mainly on sun-exposed areas.  Lesions characteristically have brown, black, red, and white areas and become more irregularly pigmented over time.  Risk of conversion to melanoma by age 75 is estimated at 1 to 2 %.  Patients should undergo regular follow-up examinations for signs of conversion to melanoma.  Because conversion to melanoma is usually relatively slow, the decision to excise lentigo maligna should be based on several factors, including the size and location of the lesion, which determines the complexity of the procedure required, and the patient's life expectancy and comorbidities.

A hemangioma is a benign tumor consisting chiefly of dilated or newly formed blood vessels. A port wine stain is a reddish purple superficial hemangioma of the skin commonly occurring as a birthmark.

Pirouzmanesh and colleagues (2003) noted that pilomatrixoma, also known as calcifying epithelioma of Malherbe, is a benign skin neoplasm that arises from hair follicle matrix cells.  Pilomatrixoma is a common skin neoplasm in the pediatric population that is often mis-diagnosed as other skin conditions.  This study reviewed an 11-year experience at a tertiary children's hospital, examining the cause, clinical and histopathological presentation, management, and treatment outcomes of pilomatrixoma.  A review of the pathology database at Children's Hospital Los Angeles revealed 346 pilomatrixomas excised from 336 patients between 1991 and 2001.  The hospital charts, pathology records, and plastic surgery clinic charts were reviewed with respect to variables such as sex, age at the time of presentation, clinical and histopathological presentation, pre-operative diagnosis, management, recurrence, and treatment outcome.  The main presenting symptom was a hard, subcutaneous, slowly growing mass.  The pre-operative diagnosis was accurate and consistent with the pathological diagnosis of pilomatrixoma in only 100 cases (28.9 %).  This entity should be considered with other benign or malignant conditions in the clinical differential diagnosis of solitary firm skin nodules, especially those on the head, neck, or upper limbs.  The diagnosis can generally be made with a clinical examination.  Imaging studies are not required unless symptoms or the location of the lesion warrants such diagnostic assessments.  The treatment of choice is surgical excision, and the recurrence rate is low.

Roche et al (2010) stated that a pilomatricoma, also known as pilomatrixoma or calcifying epithelioma of Malherbe, is a benign skin tumor arising from the hair follicle matrix.  This tumor is common in children and young adults, especially in the head and neck region.  However, pilomatricomas are frequently mis-diagnosed or not recognized.  The history is typical of a slowly enlarging mass, irregularly contoured; it is fixed to the skin but slides freely over the, underlying tissues, often with a discoloration that varies from red to purple-bluish.  Ultrasound examination, magnetic resonance imaging, and fine-needle aspiration can be helpful if the diagnosis is uncertain.  Spontaneous regression has never been observed and malignant degeneration is very rare.  Surgical excision with clear margins is the treatment of choice, otherwise recurrence may occur due to incomplete resection.

Guinot-Moya et al (2011) determined the incidence and clinical features of patients diagnosed with pilomatrixoma.  A retrospective analysis was made of 205 cases of pilomatrixoma diagnosed according to clinical and histological criteria, with an evaluation of the incidence, patient age at presentation, gender, lesion location and size, single or multiple presentation, differential diagnosis, histopathological and clinical findings and relapses.  Pilomatrixoma was seen to account for 1.04 % of all benign skin lesions.  It tended to present in pediatric patients – almost 50 % corresponding to individuals under 20 years of age – with a slight male predilection (107/98).  Approximately 75 % of all cases presented as single lesions measuring less than 15 mm in diameter.  Multiple presentations were seen in 2.43 % of cases.  The most frequent locations were the head and orofacial zones (particularly the parotid region), with over 50 % of all cases, followed by the upper (23.9 %) and lower limbs (12.7 %).  Only 1 relapse was documented following simple lesion excision.  The authors concluded that the frequency of pilomatrixomas was 1.04 % of all benign skin lesions – the lesions being predominantly located in the maxillofacial area.  Due to the benign features of this disorder, simple removal of the lesion is considered to be the treatment of choice, and is associated with a very low relapse rate.

Porokeratosis is a disorder of keratinization characterized by one or more atrophic macules or patches surrounded by a distinctive hyperkeratotic ridge-like border called a cornoid lamella (Spencer, 2011; Spencer, 2012). The coronoid lamella is a a thin column of closely stacked, parakeratotic cells extending through the stratum corneum with a thin or absent granular layer. Multiple clinical variants of porokeratosis exist. The most commonly described variants include: disseminated superficial actinic porokeratosis (DSAP), disseminated superficial porokeratosis (DSP), classic porokeratosis of Mibelli, linear porokeratosis, porokeratosis plantaris palmaris et disseminata, and punctate porokeratosis. The diagnosis of porokeratosis often can be made based solely on clinical examination (Spencer, 2011; Spencer, 2012). The clinical appearance of an atrophic macule or patch with a well-defined, raised, hyperkeratotic ridge suggests this disorder. Biopsies are typically performed when the appearance of the lesion is not classic or when there is concern for malignant transformation. Malignant transformation has occurred in patients with all major variants of porokeratosis with the exception of punctate porokeratosis. It is estimated to occur in 7.5 to 11 percent of patients, with an average period to cancer onset of 36 years (Spencer, 2011; Spencer, 2012). Linear porokeratosis and giant porokeratosis (a manifestation of porokeratosis of Mibelli) are the variants most susceptible to malignant transformation, while this occurrence in DSAP is rare. Although removal of lesions via surgical or destructive methods is an option for the prevention of malignant transformation in lesions of porokeratosis, the need to do so is questionable (Spencer, 2011; Spencer, 2012). Factors such as the estimated risk for malignancy for specific lesion types and the risk for significant cosmetic or functional defects following removal must be considered. The removal of the lesions with the greatest risk for malignancy (linear porokeratosis or large porokeratosis of Mibelli) often would result in an unfavorable amount of scarring. Moreover, the large number of lesions and low risk for malignancy in individual lesions of DSAP or DSP suggest that the benefit of lesion removal for the prevention of malignancy in these variants is likely to be minima (Spencer, 2011; Spencer, 2012). The ability to clinically follow lesions of porokeratosis for signs or symptoms of malignancy and the high likelihood of successful treatment of malignancy once it develops support clinical surveillance as an acceptable method of management, and thus, most patients with porokeratosis are followed clinically (Spencer, 2011; Spencer, 2012). Lesions suggestive of malignancy require excision, whereby micrographic surgery offers a precise way of separating the tumor from its porokeratotic background (Sertznig, et al., 2012). Although nonexcisional destructive methods (.g., laser, cryotherapy) has been used to remove isolated porokeratosis lesions, there are no studies showing the value of prophylactic non-excisional surgical treatment in reducing the incidence of malignancy in cases of porokeratosis (Sertznig, et al., 2012). If the decision is made to excise or destroy a lesion for prophylactic purposes, doing so in an urgent manner is not necessary, as the period between lesion development and malignancy often spans decades. After removal, clinical follow-up still should be performed yearly to evaluate these patients for the development of new or recurrent lesions (Spencer, 2011; Spencer, 2012).

Cutaneous and Subcutaneous Neurofibromas

An UpToDate review on "Neurofibromatosis type 1 (NF1): Management and prognosis" (Korf, 2015) states that "Cutaneous and subcutaneous neurofibromas are not removed unless there is a specific need for removal (e.g., pain, bleeding, interference with function, disfigurement).  Referral to dermatology is advised for patients with severe pruritus".

Cutaneous Skeletal Hypophosphatemia Syndrome

Ovejero and colleagues (2016) stated that cutaneous skeletal hypophosphatemia syndrome (CSHS), caused by somatic RAS mutations, features excess fibroblast growth factor-23 (FGF23) and skeletal dysplasia.  In this study, records from 56 individuals were reviewed and demonstrated fractures, scoliosis, and non-congenital hypophosphatemia that in some cases were resolved.  Phosphate and calcitriol, but not skin lesion removal, were effective at controlling hypophosphatemia.  No skeletal malignancies were found; 5 CSHS subjects underwent prospective data collection at clinical research centers.  A review of the literature identified 45 reports that included a total of 51 additional patients, in whom the findings were compatible with CSHS.  Data on nevi subtypes, bone histology, mineral and skeletal disorders, abnormalities in other tissues, and response to treatment of hypophosphatemia were analyzed.  Fractures, limb deformities, and scoliosis affected most CSHS subjects.  Hypophosphatemia was not present at birth.  Histology revealed severe osteomalacia but no other abnormalities.  Skeletal dysplasia was reported in all anatomical compartments, though less frequently in the spine; there was no clear correlation between the location of nevi and the skeletal lesions.  Phosphate and calcitriol supplementation was the most effective therapy for rickets.  Convincing data that nevi removal improved blood phosphate levels was lacking.  An age-dependent improvement in mineral abnormalities was observed.  A spectrum of extra-osseous/extra-cutaneous manifestations that included both benign and malignant neoplasms was present in many subjects, though osteosarcoma remains un-reported.

Needle Hyfrecation for Sebaceous Hyperplasia

Hyfrecation refers to the use of a device that is designed for use in electro-surgery on conscious patients, usually in the office-setting.  A hyfrecator is used to destroy tissue directly, and to stop bleeding during minor surgery.  It works by emitting low-power, high-frequency, high-voltage AC electrical pulses, via an electrode mounted on a hand-piece, directly to the affected area of the body.

Bader and Scarborough (2010) noted that sebaceous hyperplasia is a common, benign proliferation of sebaceous glands occurring predominantly on the face.  Clinically, there is 1 or several, 2- to 4-mm yellowish papules, often with a central umbilication representing the site of a ductal opening.  Sebaceous hyperplasia has been found to occur with an increased frequency in patients receiving hemodialysis or immunosuppressive therapy, especially after kidney transplantation.  Most often these lesions represent little more than a cosmetic concern, although they may be confused clinically with basal cell carcinoma.

An UpToDate review on "Cutaneous adnexal tumors" (North et al, 2019) states that "Sebaceous hyperplasia is a relatively common lesion resulting from the enlargement of normal sebaceous glands.  Sebaceous hyperplasia is not a true tumor, but shares clinical and histopathologic features with sebaceous adenoma.  It typically presents as 2- to 6-mm umbilicated, skin-colored to yellowish or brownish papules on the forehead, nose, and cheeks of older individuals.  Rarely, lesions can occur on the areola, genitalia, and anterior chest, sometimes in a linear configuration ("juxtaclavicular beaded lines").  Sebaceous hyperplasia has been reported in 15 to 30 % of transplant patients treated with cyclosporine.  The so-called premature sebaceous hyperplasia presents with multiple discrete or plaque-like lesions in children and adolescents and is considered a hamartomatous lesion related to nevus sebaceous … Treatment is for cosmetic reasons and includes electrosurgery, cryosurgery, shave removal, dermabrasion, laser therapy, and oral isotretinoin".

Dermatosis Papulosa Nigra

Tran and Richer (2020) noted that dermatosis papulosa nigra is a benign skin lesion found most frequently on the face of patients with skin of color; and elective treatment is requested periodically.  However, in view of knowledge gaps regarding aesthetic treatments for skin of color, patients can be exposed to unnecessary risks or simply denied treatment options due to physician reservation.  Cosmetic treatments should balance efficacy of lesion removal while minimizing pigmentary complications.  These investigators described the few published therapeutic modalities for dermatosis papulosa nigra.  Alongside established surgical techniques, laser devices including the 532-nm potassium-titanylphosphate laser, 532-nm diode laser, 585-nm pulsed dye laser, 1064-nm neodymium-doped yttrium aluminum garnet laser, 1550-nm erbium-doped fractionated laser and the 10,600-nm carbon dioxide laser have been successfully reported.

Furthermore, an UpToDate review on “Overview of benign lesions of the skin” (Goldstein and Goldstein, 2021) states that “Benign skin lesions that occur in adults and children include … Epidermal tumors (seborrheic keratosis, dermatosis papulosa nigra)”.

Poikiloderma of Civatte

In a systematic review, Wat and colleagues (2014) provided evidence-based recommendations to guide physicians in the application of intense pulsed light (IPL) for the treatment of dermatologic disease.  These researchers carried out a literature search of the CENTRAL (1991 to May 6, 2013), Embase (1974 to May 6, 2013), and Medline in-process and non-indexed citations and Medline (1964 to present) databases.  Studies that examined the role of IPL in primary dermatologic disease were identified, and multiple independent investigators extracted and synthesized data.  Recommendations were based on the highest level of evidence available.  Level 1 evidence was found for the use of IPL for the treatment of melasma, acne vulgaris, and telangiectasia.  Level 2 evidence was found for the treatment of lentiginous disease, rosacea, capillary malformations, actinic keratoses, and sebaceous gland hyperplasia.  Level 3 or lower evidence was found for the treatment of poikiloderma of Civatte, venous malformations, infantile hemangioma, hypertrophic scars, superficial basal cell carcinoma, and Bowen's disease.  The authors concluded that IPL was an effective treatment modality for a growing range of dermatologic disease and in some cases may represent a treatment of choice.  It is typically well-tolerated.  Moreover, these researchers stated that further high-quality studies are needed.

Furthermore, an UpToDate review on “Acquired hyperpigmentation disorders” (Vashi and Kundu, 2021) states that “Poikiloderma of Civatte (PC) is a common disorder characterized by mottled pigmentation (hyper- and hypopigmentation), skin atrophy, and telangiectasias involving the lateral aspect of the face, neck, and V of chest caused by chronic exposure to UV radiation.  The submental area is typically spared … PC has a chronic, progressive, and irreversible course that continues with exposure to UV light.  Photoprotection is an essential part of management.  Therapies directed at reducing the hyperpigmentation and the telangiectatic component include intense pulsed light and non-ablative fractional laser”.

Appendix

Pre-Malignant Skin Lesions (not an all-inclusive list)

• Actinic keratosis
• Lentigo maligna
• Leukoplakia
• Squamous cell carcinoma in-situ (Bowen's disease)

Skin Lesions That Do Not Qualify as Pre-Malignant (not an all-inclusive list)

• Acrochordons (skin tags)
• Cherry angioma
• Dermatofibroma
• Hemangioma (superficial or deep)
• Neurofibroma
• Nevus flammeus (port-wine stain)
• Nevus simplex
• Pyogenic granuloma
• Seborrheic keratosis
• Telangiectasia
• Verruca vulgaris (warts)

Table: CPT Codes / HCPCS Codes / ICD-10 Codes

Code	Code Description
Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":
Pre-Malignant Lesions:
CPT codes covered if selection criteria are met:
17000 - 17004	Destruction, (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses)
ICD-10 codes covered if selection criteria are met:
D04.0 - D04.9	Carcinoma in situ of skin [Bowen's disease, lentigo maligna]
K13.21	Leukoplakia of oral mucosa, including tongue
L57.0	Actinic keratosis
Benign Lesions:
CPT codes covered if selection criteria are met:
11200 - 11201	Removal of skin tags, multiple fibrocutaneous tags, any area
11300 - 11313	Shaving of epidermal or dermal lesions
11400 - 11446	Excision, benign lesions
17110 - 17111	Destruction, (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular lesions
54050 - 54065	Destruction of lesion(s), penis (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle)
56501 - 56515	Destruction of lesion(s), vulva
57061 - 57065	Destruction of vaginal lesion(s)
64788	Excision of neurofibroma or neurolemmoma; cutaneous nerve
64790	Excision of neurofibroma or neurolemmoma; major peripheral nerve
64792	Excision of neurofibroma or neurolemmoma; extensive (including malignant type)
64788	Excision of neurofibroma or neurolemmoma; cutaneous nerve
64790	Excision of neurofibroma or neurolemmoma; major peripheral nerve
64792	Excision of neurofibroma or neurolemmoma; extensive (including malignant type)
CPT codes not covered for indications listed in the CPB:
0419T	Destruction neurofibroma, extensive, (cutaneous, dermal extending into subcutaneous); face, head and neck, greater than 50 neurofibroma
0420T	Destruction neurofibroma, extensive, (cutaneous, dermal extending into subcutaneous); trunk and extremities, extensive, greater than 100 neurofibroma
ICD-10 codes covered if selection criteria are met:
A63.0	Anogenital (venereal) warts
B07.0 - B07.9	Viral warts [* note - report 17110-17111 per AMA CPT guidelines]
B08.1	Molluscum contagiosum
D04.0 - D04.9	Carcinoma in situ of skin [Bowen's disease, lentigo maligna]
D17.0 - D17.39	Benign lipomatous neoplasm of skin and subcutaneous tissue
D18.00 - D18.09	Hemangioma [superficial or deep]
D22.0 - D22.9	Melanocytic nevi
D23.0 - D23.9	Other benign neoplasm of skin
D36.10 - D36.9	Benign neoplasm of other and unspecified sites [neurofibroma]
D48.5	Neoplasm of uncertain behavior of skin [dysplastic nevus syndrome]
I78.1	Nevus, non-neoplastic [nevus simplex, telangiectasia, cherry angioma]
L72.0	Epidermal cyst
L72.3	Sebaceous cyst
L82.0 - L82.1	Seborrheic keratosis [not covered for the removal of dermatosis papulosa nigra]
L91.0 - L91.9	Hypetrophic scar [acrochordons, skin tags]
L98.0	Pyogenic granuloma
Q82.5	Congenital non-neoplastic nevus [nevus flammeus, port-wine stain]
ICD-10 codes not covered for indications listed in the CPB:
L57.3	Poikiloderma of civatte
L73.8	Other specified follicular disorders [sebaceous hyperplasia]

The above policy is based on the following references: